Literature DB >> 11332283

Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.

I N Shaw1, M M Natrajan, G S Rao, K Jesudasan, M Christian, M Kavitha.   

Abstract

Forty-six, newly detected, previously untreated multibacillary (MB) patients with a bacterial index (BI) of > or = 3+ who had received WHO/MDT for 2 years were followed up for a total duration of 424 person-years and a mean duration of 9.26 +/- 2.98 years per patient. The BIs of the patients continued to fall, and all of the patients, except one, reached skin-smear negativity. WHO/MDT was well accepted and well tolerated. Relapse, which was defined as an increase in the BI of 1+ or more with or without clinical evidence of activity, was observed in only one patient, giving a relapse rate of 2.2% or 0.23 per 100 person-years in patients with a BI of > or = 3+ after long-term follow up. This patient was started on a second course of WHO/MDT to which he responded favorably. WHO/MDT for a fixed duration of 2 years for MB patients as recommended by the WHO is vindicated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11332283

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  5 in total

Review 1.  Leprosy.

Authors:  W Cairns S Smith; Paul Saunderson
Journal:  BMJ Clin Evid       Date:  2010-06-28

Review 2.  Leprosy.

Authors:  Diana Nj Lockwood
Journal:  BMJ Clin Evid       Date:  2007-04-01

3.  Peripheral Neuropathy Due to Leprosy.

Authors:  Sharon P. Nations; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

Review 4.  A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.

Authors:  Carlijn G N Voorend; Erik B Post
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

5.  Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study.

Authors:  Anil Kumar; Anita Girdhar; B K Girdhar
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.